Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases

  title={Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases},
  author={Tsuneo Takenaka and Hiroshi Takane and Hirokazu Okada and Yoichi Ohno and Hiromichi Suzuki},
  journal={NDT Plus},
  pages={192 - 193}
Sir, In 2004, the Japanese Society of Hypertension recommended calcium channel blockers (CCBs) as second line drugs, with the renin–angiotensin (Ang) system (RAS) inhibitor as the first choice, for the treatment of hypertension associated with chronic kidney disease (CKD). We reported that augmentation index (AI) is related to proteinuria in CKD patients, and that RAS inhibition preserves arterial compliance in CKD [1,2]. However, the effects of CCBs on arterial stiffness remain unclear… 
Long-Term Effects of Calcium Antagonists on Augmentation Index in Hypertensive Patients with Chronic Kidney Disease: A Randomized Controlled Study
In hypertensive patients with CKD, combined treatment with AZ and an ARB decreases proteinuria and preferentially improves arterial reflection.
Amlodipine and Loop Diuretics as the Second Anti-Hypertensive Medication for the Treatment of Hypertension with Chronic Kidney Diseases
Calcium antagonists appear suited for adding on renin angiotensin system inhibitors to treat hypertension with CKDs, and improved AI more strongly than diuretics.
Improvements in Augmentation Index and Urinary Albumin Excretion With Benidipine in Hypertensive Patients With Chronic Kidney Disease.
It is suggested that benidipine might reduce significantly AI and might have potentially greater improvements in UAE than amlodipine in advanced CKD patients receiving RAS inhibitors.
One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.
Benidipine treatment reduced the urinary protein to creatinine ratio in hypertensive patients with CKD, and the percentage decrease of the UP/cre ratio was greater in elderly patients, suggesting that benidIPine may have more potent antiproteinuric effects in elderly hypertensive Patients with CKd.
Administration of an Angiotensin-Converting Enzyme Inhibitor Improves Vascular Function and Urinary Albumin Excretion in Low-Risk Essential Hypertensive Patients Receiving Anti-Hypertensive Treatment with Calcium Channel Blockers. Organ-Protecting Effects Independent of Anti-Hypertensive Effect
In low-risk hypertensive patients, perindopril improves renal and vascular function probably via its persistent anti-hypertensive effects and the concomitant effects of CCB.
Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
In hypertensive patients treated with ARB and CCB, benidipine exhibits a better renoprotective effect than other drugs of this class (amlodipine and nifedipine CR).
Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension
It is demonstrated that benidipine favourably affects renal function in patients with essential hypertension compared with amlodipine, suggesting that the clinical benefits of benidIPine as an antihypertensive drug include a renoprotective effect.
Height Constitutes an Important Predictor of Mortality in End-Stage Renal Disease
These findings provide new evidence that shortness in height independently contributes to total mortality in hemodialysis patients and implicated that high AI, the presence of diabetes, and low high-density lipoprotein cholesterol were significant contributors to cardiovascular events.
Prognostic effects of calcium channel blockers in patients with vasospastic angina--a meta-analysis.
Benidipine showed significantly more beneficial prognostic effects than others among the 4 major CCB that effectively suppress VSA attacks in general, according to a meta-analysis regarding the effects of CCB on major adverse cardiovascular events (MACE).
Interactions between CKD and MetS and the Development of CVD
For this special issue, front-line researchers and authors were asked to submit original research and review articles on the interactions between CKD and MetS and the development of CVD to provide pivotal evidence for understanding the pathophysiological relationships among the disorders on a clinical basis and a molecular basis.


Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases
The present results provided the evidence that angiotensin inhibition arrested a time-dependent elevation of haPWV in non-diabetic CKDs, conferring organ protection.
Qualification of Arterial Stiffness as a Risk Factor to the Progression of Chronic Kidney Diseases
The present data indicate that AI as well as angiotensin contribute to the development of left ventricular hypertrophy and suggest that in addition to ang Elliotensin, AI is a risk factor of progression of non-diabetic CKDs.
Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II.
The data provide evidence that Ang II elicits IP3CR, possibly inducing a cellular response that activates voltage-dependent calcium channels on afferent arterioles, and calcium influx sensitive to SKF-96365.
Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.
Patients with chronic renal disease given a 48-week efonidipine treatment showed reduced proteinuria, and this effect was seen even when mean arterial blood pressure failed to become less than 100 mmHg, suggesting T-type Ca(2+) channel blockade provides beneficial action in renal injury.
ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells.
It is suggested that ClC-5 may be essential for proximal tubular endocytosis by providing an electrical shunt necessary for the efficient acidification of vesicles in theendocytotic pathway, explaining the proteinuria observed in Dent's disease.